N-(tert-butoxycarbonyl)-6-methoxyanthranilic acid | 136247-94-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(tert-butoxycarbonyl)-6-methoxyanthranilic acid
• 英文别名: 2-[(tert-butoxycarbonyl)amino]-6-methoxybenzoic acid；2-((Tert-butoxycarbonyl)amino)-6-methoxybenzoic acid；2-methoxy-6-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid
• CAS: 136247-94-4
• 化学式: C₁₃H₁₇NO₅
• 分子量: 267.282
• InChiKey: QBZYEHBJAHDOSG-UHFFFAOYSA-N

物化性质

• 沸点：
  354.5±32.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl)-6-methoxyanthranilic acid 在 盐酸 、 lithium methanethiolate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 6-羟基邻氨基苯甲酸
  参考文献：
  名称：

  Studies on nitrogen metabolism using carbon-13 NMR spectroscopy. 6. Biosynthesis of sarubicin A. Synthesis and incorporation of 6-hydroxy[13CO15NH2]anthranilamide

  摘要：

  We have previously demonstrated that 6-hydroxyanthranilic acid (3) is specifically incorporated into sarubicin A (1) by Streptomyces helicus. 6-Hydroxyanthranilamide (4) has now been synthesized in five steps from m-anisidine in a manner that allowed efficient introduction of isotope labels to prepare [(CONH2)-C-13-N-15]-4a. A new synthesis of 3 from m-anisidine has also been developed. 4a was fed to S. helicus, and a 1.29% incorporation into 1b was obtained. Examination of the C-13 NMR spectrum of 1b revealed predominantly intact incorporation, with a minor amount of 4a (0.13%) first undergoing in vivo hydrolysis to the corresponding acid. Thus, carboxamide formation is the next step in the biosynthesis of 1.

  DOI：

  10.1021/jo00023a036
• 作为产物：
  描述：

  间氨基苯甲醚 在 叔丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 54.0h， 生成 N-(tert-butoxycarbonyl)-6-methoxyanthranilic acid
  参考文献：
  名称：

  Studies on nitrogen metabolism using carbon-13 NMR spectroscopy. 6. Biosynthesis of sarubicin A. Synthesis and incorporation of 6-hydroxy[13CO15NH2]anthranilamide

  摘要：

  We have previously demonstrated that 6-hydroxyanthranilic acid (3) is specifically incorporated into sarubicin A (1) by Streptomyces helicus. 6-Hydroxyanthranilamide (4) has now been synthesized in five steps from m-anisidine in a manner that allowed efficient introduction of isotope labels to prepare [(CONH2)-C-13-N-15]-4a. A new synthesis of 3 from m-anisidine has also been developed. 4a was fed to S. helicus, and a 1.29% incorporation into 1b was obtained. Examination of the C-13 NMR spectrum of 1b revealed predominantly intact incorporation, with a minor amount of 4a (0.13%) first undergoing in vivo hydrolysis to the corresponding acid. Thus, carboxamide formation is the next step in the biosynthesis of 1.

  DOI：

  10.1021/jo00023a036

文献信息

• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• 一种芳胺邻位取代的化合物的制备方法
  申请人：联化科技股份有限公司

  公开号：CN110396108A

  公开（公告）日：2019-11-01

  本发明公开了一种如式I所示的芳胺邻位取代的化合物的制备方法。本发明提供的制备方法，其包括如下步骤，步骤(1)、在连续流反应器中，将物料1和烷基锂试剂进行锂化反应；得到含如式III所示的金属锂化合物的溶液；所述的物料1为如式II所示的芳胺类化合物与有机溶剂的混合溶液；步骤(2)、在连续流反应器中，将物料2和步骤(1)中得到的含如式III所示的金属锂化合物的溶液进行偶联反应，得到如式I所示的芳胺邻位取代的化合物即可。采用本发明的制备方法可在室温下实现芳环上的锂化反应制备成相应的溴代、硼酸、醛、羧酸等产物，反应时间短，减少了易燃物料的和高反应活性中间体的在线量，提高了安全性。
• US7491718B2
  申请人：——

  公开号：US7491718B2

  公开（公告）日：2009-02-17
• [EN] 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 2-(INDAZOL-5-YL)-6-(PIPÉRIDIN-4-YL)-1,7-NAPHTYRIDINE ET COMPOSÉS ASSOCIÉS UTILES COMME MODULATEURS POUR L'ÉPISSAGE D'ACIDES NUCLÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：[en]REMIX THERAPEUTICS INC.

  公开号：WO2023133217A1

  公开（公告）日：2023-07-13

  The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.